Coutré, S. E., Furman, R. R., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., . . . O’Brien, S. (2017). Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Cancer Res.
Chicago Style CitationCoutré, Steven E., et al. "Extended Treatment With Single-agent Ibrutinib At the 420 Mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma." Clin Cancer Res 2017.
MLA CitationCoutré, Steven E., et al. "Extended Treatment With Single-agent Ibrutinib At the 420 Mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma." Clin Cancer Res 2017.
Warning: These citations may not always be 100% accurate.